Clopidogrel - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:21Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:58, 20 March 2026
Line 85:		Line 85:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:25:50Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:25, 20 March 2026
Line 87:		Line 87:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:44:00Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 74: / Line 74: @@
 *Excretion: urine 50%, feces 46%
 *Mechanism of Action: irreversibly binds to P2Y12 adenosine diphosphate receptors, reducing platelet activation and aggregation
 ==See Also==

Elcatracho: /* See Also */

2021-03-06T02:48:44Z

Elcatracho: /* General */

2021-03-06T02:43:42Z

General

← Older revision		Revision as of 02:43, 6 March 2021
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Antiplatelet]]		*Type: [[Antiplatelet]]
	*Dosage Forms: 75, ~~300~~ PO		*Dosage Forms: 75mg, 300mg PO
	*Common Trade Names: Plavix		*Common Trade Names: Plavix

Mholtz at 06:29, 13 July 2017

2017-07-13T06:29:58Z

← Older revision		Revision as of 06:29, 13 July 2017
Line 76:		Line 76:

	==See Also==		==See Also==


	==References==		==References==
			<references/>

	~~<references/>~~
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Mholtz: Text replacement - "qd" to "QD"

2017-07-07T07:15:19Z

Text replacement - "qd" to "QD"

← Older revision		Revision as of 07:15, 7 July 2017
Line 21:		Line 21:

	===Post-[[Acute coronary syndrome]]===		===Post-[[Acute coronary syndrome]]===
	*[[Unstable angina]], [[NSTEMI]]: Start 300mg PO x 1, then 75mg PO qd		*[[Unstable angina]], [[NSTEMI]]: Start 300mg PO x 1, then 75mg PO QD
	*[[STEMI]]: 75mg/day PO (in combination with [[aspirin]] 162-325mg/day		*[[STEMI]]: 75mg/day PO (in combination with [[aspirin]] 162-325mg/day
	*Recent MI, [[Stroke]], or [[Peripheral Arterial Disease]]: 75mg PO qd		*Recent MI, [[Stroke]], or [[Peripheral Arterial Disease]]: 75mg PO QD

	===Thrombotic event prevention===		===Thrombotic event prevention===
	*75mg PO qd		*75mg PO QD

	==Pediatric Dosing==		==Pediatric Dosing==

Kxl328: /* Age and Indication Related DosagesSabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.Mehta SR et al. Double-dose versus standard-dose c...

2017-06-23T23:38:18Z

/* Age and Indication Related DosagesSabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.Mehta SR et al. Double-dose versus standard-dose c...

← Older revision		Revision as of 23:38, 23 June 2017
Line 7:		Line 7:
	===Age and Indication Related Dosages<ref>Sabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.</ref><ref>Mehta SR et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43.</ref><ref>The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345:494-502.</ref>===		===Age and Indication Related Dosages<ref>Sabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.</ref><ref>Mehta SR et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43.</ref><ref>The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345:494-502.</ref>===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|''''''		\| align="center" style="background:#f0f0f0;"\|'''''
	\| align="center" style="background:#f0f0f0;"\|'''Trial'''		\| align="center" style="background:#f0f0f0;"\|'''Trial'''
	\| align="center" style="background:#f0f0f0;"\|'''Age < 75'''		\| align="center" style="background:#f0f0f0;"\|'''Age < 75'''

Rossdonaldson1: /* Serious */

2016-12-19T08:11:32Z

Serious

← Older revision		Revision as of 08:11, 19 December 2016
Line 62:		Line 62:
	*[[toxic epidermal necrolysis]]		*[[toxic epidermal necrolysis]]
	*[[erythema multiforme]]		*[[erythema multiforme]]
	*drug rash with eosinophilia and systemic sx		*drug rash with eosinophilia and systemic symptoms
	*Eosinophilic pneumonia		*Eosinophilic pneumonia

Rossdonaldson1: /* Age and Indication Related DosagesSabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.Mehta SR et al. Double-dose versus standard-dose c...

2016-12-19T08:11:11Z

← Older revision		Revision as of 08:11, 19 December 2016
Line 12:		Line 12:
	\| align="center" style="background:#f0f0f0;"\|'''Age > 75'''		\| align="center" style="background:#f0f0f0;"\|'''Age > 75'''
	\|-		\|-
	\| STEMI with fibrinolysis\|\|CLARITY\|\|300 mg\|\|75 mg		\| [[STEMI]] with fibrinolysis\|\|CLARITY\|\|300 mg\|\|75 mg
	\|-		\|-
	\| STEMI with PCI\|\|OASIS-7\|\|600 mg\|\|300 mg		\| [[STEMI]] with PCI\|\|OASIS-7\|\|600 mg\|\|300 mg
	\|-		\|-
	\| NSTEMI/UA with ischemic EKG changes\|\|CURE\|\|300 mg\|\|75 mg		\| [[NSTEMI]]/[[Unstable angina\|UA]] with ischemic EKG changes\|\|CURE\|\|300 mg\|\|75 mg
	\|-		\|-
	\|}		\|}

	===Post-[[Acute coronary syndrome]]===		===Post-[[Acute coronary syndrome]]===
	*[[Unstable angina]], [[NSTEMI]]: Start 300mg PO x 1, then 75mg PO qd		*[[Unstable angina]], [[NSTEMI]]: Start 300mg PO x 1, then 75mg PO qd

← Older revision		Revision as of 23:38, 23 June 2017
Line 7:		Line 7:
	===Age and Indication Related Dosages<ref>Sabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.</ref><ref>Mehta SR et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43.</ref><ref>The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345:494-502.</ref>===		===Age and Indication Related Dosages<ref>Sabatine MS et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005; 352:1179-1189.</ref><ref>Mehta SR et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43.</ref><ref>The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345:494-502.</ref>===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|''''''		\| align="center" style="background:#f0f0f0;"\|'''''
	\| align="center" style="background:#f0f0f0;"\|'''Trial'''		\| align="center" style="background:#f0f0f0;"\|'''Trial'''
	\| align="center" style="background:#f0f0f0;"\|'''Age < 75'''		\| align="center" style="background:#f0f0f0;"\|'''Age < 75'''

← Older revision		Revision as of 02:48, 6 March 2021
Line 76:		Line 76:

	==See Also==		==See Also==
			*[[Antiplatelet medications]]
			*[[Antiplatelet agent reversal]]

	==References==		==References==